Issue: May 2017
May 17, 2017
1 min read

Research underway on cannabinoid-based treatment approach to neuropathic pain in dry eye

Issue: May 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Novaliq, in collaboration with the University of Cologne, Germany, announced the successful application of a novel cannabinoid-based treatment approach to neuropathic ocular pain and inflammation associated with dry eye disease.

The new drug formulation has been successfully proof-tested in a consecutive research program, Nov-07, and is now undergoing conformational studies for a phase 1 clinical trial.

“Increasing evidence is available on the importance of neuropathic ocular pain in DED,” Philipp Steven, MD, principal investigator, Ocular Surface Group at the Department of Ophthalmology, University of Cologne, said in a press release. “Based on the preclinical results, we believe that the Nov-07 program will facilitate the treatment of DED utilizing a dual mode of action towards inflammation and ocular neuropathic pain.”

The neuroprotective and pain-sedating properties of molecules that target the cannabinoid receptor system are well known, according to the release, but poor solubility, instability and fast autoxidation in water have been limitations to their use in the eye. EyeSol technology, Novaliq’s proprietary new-concept drug delivery platform, may enhance topical bioavailability, stability and efficacy of cannabinoid molecules in an eye drop formulation.

“With this program we demonstrate the power of EyeSol as an enabling technology for developing truly differentiated drugs with the ability to transform ocular therapeutics by overcoming the current limitations of water in eye care,” Christian Roesky, PhD, managing director and CEO, Novaliq, said in the release.